PRP Systems
We are pursuing growth opportunities for the use of the AutoloGel™ System in hair transplantation and the Angel® System in orthopedics, as well as actively seeking complementary products for wound care markets. Plans are underway to upgrade our AutoloGel™ System technology with the design of a new semi-closed blood separation device that will streamline the PRP process making the clinical procedure more efficient, reducing the margin of error and optimizing waste management.

ActivAT®
Our Autologous Thrombin Processing Kit (ActivAT®) is designed to produce autologous thrombin serum from platelet poor plasma providing an autologous alternative to bovine-derived products. Thrombin is a blood coagulation factor that can facilitate blood clotting and platelet activation. The use of PPP to produce autologous thrombin avoids the loss of valuable PRP. The activAT® kit is sold exclusively in Europe and Canada, and ActivAT® is sold as an adjunct to the Angel®. It produces 5 to 6 ml of thrombin from 12 ml of PPP in approximately 30 minutes of processing time. 

Anti-inflammatory Peptide
CT-112 is an anti-inflammatory octapeptide that has demonstrated in pre-clinical studies its potential for therapeutic use in autoimmune diseases, such as rheumatoid arthritis, graft-versus-host disease, chronic obstructive pulmonary disease, reperfusion injury and atherosclerosis. Target markets under evaluation for commercialization of CT-112 include Pyoderma Gangrenosum (PG), atopic dermatitis, and an anti-inflammatory coating for medical devices. We have undertaken studies in human cell systems to provide CT-112 potency estimates to facilitate further development of this promising biological compound. Negotiations with strategic partners are underway regarding development of the CT-112 candidate as a coating for medical devices.